A phase III, randomised, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimisation safety and efficacy study of lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6-17 with attention-deficit/ hyperactivity disorder (ADHD)
Laufzeit: 01.01.2008 - 31.12.2010
imported
Kurzfassung
Multicentre study to be conducted within Europe (Belgium, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom) and the United States (US). 54 study sites are planned.
Coordinating Principal Investigator: David Coghill, MB BCh, (UK).
The study is designed to evaluate safety and efficacy of LDX for the treatment of ADHD in children and adolescents, aged 6-17 years, in Europe.
Beteiligte Einrichtungen
